Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Adjuvant Therapy in ALK+ NSCLC
NCT05241028Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Disease Free Survival Rate at 3 years. Started May 2022; status: recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05241028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241028.